Clinical Trials

115 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06317662 2026-03-18

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

153 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT07477457 2026-03-17

A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma

Neoplasm Metastasis, Osteosarcoma

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT05453500 2026-03-13

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Burkitt Lymphoma

NCT06738368 2026-03-13

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07078604 2026-03-12

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Triple Negative Breast Neoplasms

NCT05800366 2026-03-05

A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

41 enrolled

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06434064 2026-03-02

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Triple Negative Breast Neoplasms

NCT04322318 2026-02-24

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

256 enrolled

Genitourinary

Wilms Tumor

NCT06528496 2026-02-10

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

CNS

Neuroblastoma

NCT07125183 2026-02-05

Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

Leiomyosarcoma, Sarcoma

NCT04028063 2026-01-27

Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

65 enrolled

NCT07097363 2026-01-15

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

18 enrolled

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00501826 2026-01-07

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

160 enrolled

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06835049 2025-12-30

TNT-HYPE

24 enrolled

Hyperthermia, Sarcoma

NCT06803693 2025-12-08

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

152 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06765317 2025-11-26

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

42 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07049848 2025-11-20

SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma

50 enrolled

NCT02877303 2025-11-06

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

80 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT07002216 2025-11-03

BrECADD

48 enrolled

Hodgkin Disease

NCT07016399 2025-10-30

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

51 enrolled

Triple Negative Breast Neoplasms

NCT04679012 2025-10-07

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05645380 2025-10-07

NeoTRACT

139 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06245889 2025-09-23

NeoADAPT

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07081022 2025-08-21

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

180 enrolled

Lymphoma, B-Cell

NCT04776525 2025-08-14

Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

49 enrolled

NCT04874311 2025-08-13

TRUST

80 enrolled

Tertiary Lymphoid Structures, Neoplasm Metastasis, Sarcoma

NCT04968106 2025-08-13

TORNADO

66 enrolled

NCT06023862 2025-06-15

DOVE

198 enrolled

Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms, Adenocarcinoma, Clear Cell

NCT06034561 2025-05-16

Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

50 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06377566 2025-04-20

A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

71 enrolled

Hodgkin Disease

NCT06524583 2025-03-30

L-UteCIN

198 enrolled

Leiomyosarcoma Uterus

NCT05020860 2025-02-27

RESPONSE

185 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06704555 2024-11-26

Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma

Lymphoma, Follicular

NCT05913427 2024-08-01

PESETA

80 enrolled

Endocrine

Adrenocortical Carcinoma

NCT04535713 2024-07-05

GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma

260 enrolled

NCT06250959 2024-04-04

BEAT-ALL-2024

124 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04626791 2024-03-12

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

NCT06297512 2024-03-07

Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM).

CNS

Glioblastoma

NCT05848765 2023-11-29

REFRACT

284 enrolled

Lymphoma, Lymphoma, Follicular

NCT05963347 2023-09-01

Go-CHOP as the Frontline Therapy for PTCL

Lymphoma, T-Cell, Peripheral

NCT03899337 2023-01-09

STELLAR

105 enrolled

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04159818 2022-03-22

TONIC-2

52 enrolled